


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A 5-thio- β -D-glucopyranoside compound of the following formula or a pharmaceutically acceptable salt thereof or a hydrate thereof:



{wherein

B represents a heteroaryl group which may be substituted with any substituent,

R^{1A} , R^{2A} , R^{3A} and R^{4A} , which may be the same or different, each represent a hydrogen atom, a C_{2-10} acyl group, a C_{7-10} aralkyl group, a C_{2-6} alkoxycarbonyl group, a C_{1-6} alkoxy- C_{2-10} acyl group or a C_{1-6} alkoxy- C_{2-6} alkoxycarbonyl group,

Q^X represents N or C,

X^A represents $-(CH_2)_n-$, $-CO(CH_2)_n-$, $-C(OH)(CH_2)_n-$, $-O-(CH_2)_n-$, $-CONH(CH_2)_n-$, $-NHCO(CH_2)_n-$ (wherein n is an integer of 0 to 3), $-COCH=CH-$, $-S-$ or $-NH-$, provided that when Q^X is N, X^A represents $-(CH_2)_n-$, $-CO(CH_2)_n-$, $-C(OH)(CH_2)_n-$, $-CONH(CH_2)_n-$ (wherein n is an integer of 0 to 3) or $-COCH=CH-$, and

R^5 , R^6 , R^7 , R^8 and R^9 , which may be the same or different, each represent:

a hydrogen atom;

a halogen atom;

a hydroxyl group;

a C_{1-6} alkyl group which may be substituted with one or more substituents selected from the group consisting of a halogen atom and a hydroxyl group;

a group represented by the formula:



wherein m' represents an integer of 0 to 4, and Q' represents a formyl group, an amino group, a nitro group, a cyano group, a carboxyl group, a sulfonic acid group, an optionally halogen-substituted C_{1-6} alkoxy group, a C_{1-6} alkoxy- C_{1-6} alkoxy group, a C_{2-10} alkoxy group, a C_{2-10} acyl group, a C_{2-6} alkoxycarbonyl group, a C_{1-6} alkylthio group, a C_{1-6} alkylsulfinyl group, a C_{1-6} alkylsulfonyl group, $-NHC(=O)H$, a C_{2-10} acylamino group, a C_{1-6} alkylsulfonylamino group, a C_{1-6} alkylamino group, an N,N-di(C_{1-6} alkyl)amino group, a carbamoyl group, an N-(C_{1-6} alkyl)aminocarbonyl group, or an N,N-di(C_{1-6} alkyl)aminocarbonyl group}; or

a C_{3-7} cycloalkyl group, a C_{3-7} cycloalkyloxy group, an aryl group, a C_{7-10} aralkyl group, an aryloxy group, a C_{7-10} aralkyloxy group, a C_{7-10} aralkylamino group, a heteroaryl group, or a 4- to 6-membered heterocycloalkyl group, provided that each of these groups may be substituted with 1 to 4 substituents selected from the group consisting of a halogen atom, a hydroxyl group, a C_{1-6} alkyl group and a C_{1-6} alkoxy group}.

2. (currently amended): The compound according to claim 1, wherein X^A is $-(CH_2)_n-$ or $-CO(CH_2)_n-$ (wherein n is an integer of 0 to 3), or a pharmaceutically acceptable salt thereof or a hydrate thereof.

3. (original): The compound according to claim 1, wherein X^A is $-CH_2-$ or $-CO-$, or a pharmaceutically acceptable salt thereof or a hydrate thereof.

4. (original): The compound according to claim 1, wherein X^A is $-CH_2-$, or a pharmaceutically acceptable salt thereof or a hydrate thereof.

5. (currently amended): The compound according to any one of claims 1 to 4, wherein the moiety represented by the formula:



is a group represented by the formula:



{wherein at least one of Q^A to Q^D represents a nitrogen atom, and the other each independently represent $-C-Z^Y$, provided that when Q^D is C, any one of the ring nitrogen atoms may be substituted with Z^X

{wherein Z^X represents an optionally halogen-substituted C_{1-6} alkyl group; an optionally halogen-substituted C_{3-7} cycloalkyl group; a C_{2-10} acyl group; a C_{2-6} alkoxy carbonyl group; a phenyl or C_{7-10} aralkyl group which may be substituted with one or more substituents selected from the group consisting of a halogen atom, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, an amino group, a nitro group, a cyano group, a carboxyl group, a C_{2-10} acyl group, a C_{2-6} alkoxy carbonyl group, a C_{1-6} alkylthio group, a C_{1-6} alkylsulfinyl group, a C_{1-6} alkylsulfonyl group, a C_{2-10} acylamino group, a C_{1-6} alkylamino group, an N,N-di(C_{1-6} alkyl)amino group, an N-(C_{1-6} alkyl)aminocarbonyl group and an N,N-di(C_{1-6} alkyl)aminocarbonyl group; a pyridyl group; a

thienyl group; a furanyl group; or pyrimidinyl group, and Z^Y independently represents a hydrogen atom; a halogen atom; a C_{1-6} alkyl group which may be substituted with one or more substituents selected from the group consisting of a halogen atom, a hydroxyl group and a C_{1-6} alkoxy group; an optionally halogen-substituted C_{3-7} cycloalkyl group; a carboxyl group; or a C_{2-6} alkoxycarbonyl group}}, or a pharmaceutically acceptable salt thereof or a hydrate thereof.

6. (currently amended): The compound according to any one of claims 1 to 4, wherein the moiety represented by the formula:



is a pyrazole group represented by the formula:



{wherein when Q^A is N and Q^B is $-N-Z^1$ or when Q^A is $-N-Z^2$ and Q^B is N, Q^C represents $-C-Z^3$, or alternatively, when Q^B is N and Q^C is $-N-Z^4$ or when Q^B is $-N-Z^5$ and Q^C is N, Q^A represents $-C-Z^6$

(wherein Z^1 , Z^2 , Z^4 and Z^5 each independently represent a hydrogen atom; an optionally halogen-substituted C_{1-6} alkyl group; an optionally halogen-substituted C_{3-7} cycloalkyl group; a C_{2-10} acyl group; a C_{2-6} alkoxycarbonyl group; a phenyl or C_{7-10} aralkyl group which may be substituted with one or more substituents selected from the group consisting of a halogen atom, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, an amino group, a nitro group, a cyano group, a carboxyl group, a C_{2-10} acyl group, a C_{2-6} alkoxycarbonyl group, a C_{1-6} alkylthio group, a C_{1-6} alkylsulfanyl group, a C_{1-6} alkylsulfonyl group, a C_{2-10} acylamino group, a C_{1-6} alkylamino group, an N,N-

di(C₁₋₆ alkyl)amino group, an N-(C₁₋₆ alkyl)aminocarbonyl group and an N,N-di(C₁₋₆ alkyl)aminocarbonyl group; a pyridyl group; a thienyl group; a furanyl group; or a pyrimidinyl group, and Z³ and Z⁶ each independently represent a hydrogen atom; a halogen atom; a C₁₋₆ alkyl group which may be substituted with one or more substituents selected from the group consisting of a halogen atom, a hydroxyl group and a C₁₋₆ alkoxy group; an optionally halogen-substituted C₃₋₇ cycloalkyl group; a carboxyl group; or a C₂₋₆ alkoxy carbonyl group}}, or a pharmaceutically acceptable salt thereof or a hydrate thereof.

7. (currently amended): The compound according to any one of claims 1 to 4, wherein the moiety represented by the formula:



is a pyridyl group represented by the formula:



{wherein any one of Q¹ to Q⁴ represents N and the other each independently represent -C-Z⁷ {wherein Z⁷ represents a hydrogen atom, a halogen atom, an optionally halogen-substituted C₁₋₆ alkyl group, a C₁₋₆ alkoxy group, an amino group, a C₁₋₆ alkylamino group, an N,N-di(C₁₋₆ alkyl)amino group, a C₂₋₁₀ acylamino group, a C₂₋₁₀ acyl group or an optionally halogen-substituted C₃₋₇ cycloalkyl group}}, or a pharmaceutically acceptable salt thereof or a hydrate thereof.

8. (currently amended): The compound according to any one of claims 1 to 4,
wherein the moiety represented by the formula:



is a pyrimidinyl group represented by the formula:



{wherein when Q^1 and Q^3 are each N, Q^2 and Q^4 each independently represent $-C-Z^8$, or alternatively, when Q^2 and Q^4 are each N, Q^1 and Q^3 each independently represent $-C-Z^9$ (wherein Z^8 and Z^9 each independently represent a hydrogen atom, a halogen atom, an optionally halogen-substituted C_{1-6} alkyl group, a C_{1-6} alkoxy group, an amino group, a C_{1-6} alkylamino group, an N,N-di(C_{1-6} alkyl)amino group, a C_{2-10} acylamino group, a C_{2-10} acyl group or an optionally halogen-substituted C_{3-7} cycloalkyl group)}, or a pharmaceutically acceptable salt thereof or a hydrate thereof.

9. (currently amended): The compound according to any one of claims 1 to 4,
wherein the moiety represented by the formula:



is a pyridazinyl group represented by the formula:



{wherein Q^1 and Q^2 , Q^2 and Q^3 , or Q^3 and Q^4 each represent N, and the other each represent $-C-Z^{10}$ {wherein Z^{10} independently represents a hydrogen atom, a halogen atom, an optionally halogen-substituted C_{1-6} alkyl group, a C_{1-6} alkoxy group, an amino group, a C_{1-6} alkylamino group, an N,N-di(C_{1-6} alkyl)amino group, a C_{2-10} acylamino group, a C_{2-10} acyl group or an optionally halogen-substituted C_{3-7} cycloalkyl group}}, or a pharmaceutically acceptable salt thereof or a hydrate thereof.

10. (currently amended): The compound according to any one of claims 1 to 4, wherein the moiety represented by the formula:




is a pyrazinyl group represented by the formula:



{wherein Q^1 and Q^4 each represent N and the other each represent $-C-Z^{11}$ {wherein Z^{11} independently represents a hydrogen atom, a halogen atom, an optionally halogen-substituted C_{1-6} alkyl group, an amino group, a C_{1-6} alkoxy group, a C_{1-6} alkylamino group, an N,N-di(C_{1-6} alkyl)amino group, a C_{2-10} acylamino group, a C_{2-10} acyl group or an optionally halogen-

substituted C₃₋₇ cycloalkyl group}}, or a pharmaceutically acceptable salt thereof or a hydrate thereof.

11. (currently amended): A 5-thio-β-D-glucopyranoside compound of the following formula or a pharmaceutically acceptable salt thereof:



(wherein Z^A represents a hydrogen atom, a C₁₋₆ alkyl group, a halogen-substituted C₁₋₆ alkyl group, a C₃₋₆ cycloalkyl group, a benzyl group, a C₂₋₁₀ acyl group or a C₂₋₆ alkoxycarbonyl group, Z^B represents a C₁₋₆ alkyl group or a halogen-substituted C₁₋₆ alkyl group, R^{5B} to R^{9B}, which may be the same or different, each represent a hydrogen atom, a halogen atom, a C₁₋₆ alkyl group, a halogen-substituted C₁₋₆ alkyl group, a C₃₋₆ cycloalkyl group, a C₁₋₆ alkoxy group, a halogen-substituted C₁₋₆ alkoxy group or a C₁₋₆ alkylthio group, and R^{4B} represents a hydrogen atom, a C₂₋₁₀ acyl group or a C₂₋₆ alkoxycarbonyl group).

12. (currently amended): A pharmaceutical preparation, which comprises the 5-thio-β-D-glucopyranoside compound according to ~~any one of claims 1 to 11~~ claim 1 or a pharmaceutically acceptable salt thereof or a hydrate thereof as an active ingredient.

13. (original): The pharmaceutical preparation according to claim 12, which is an inhibitor of sodium-dependent glucose transporter 2 activity.

14. (original): The pharmaceutical preparation according to claim 13, which is a prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications.

15. (currently amended): A pharmaceutical preparation, which comprises the 5-thio- β -D-glucopyranoside compound according to ~~any one of claims 1 to 14~~claim 1 or a pharmaceutically acceptable salt thereof or a hydrate thereof, in combination with at least one drug selected from the group consisting of an insulin sensitizer selected from the group consisting of a PPAR γ agonist; a PPAR α/γ agonist; a PPAR δ agonist; and a PPAR $\alpha/\gamma/\delta$ agonist, a glycosidase inhibitor, a biguanide, an insulin secretagogue, an insulin formulation and a dipeptidyl peptidase IV inhibitor.

16. (currently amended): A pharmaceutical preparation, which comprises the 5-thio- β -D-glucopyranoside compound according to ~~any one of claims 1 to 14~~claim 1 or a pharmaceutically acceptable salt thereof or a hydrate thereof, in combination with at least one drug selected from the group consisting of a hydroxymethylglutaryl coenzyme A reductase inhibitor, a fibrate, a squalene synthase inhibitor, an acyl-coenzyme A:cholesterol acyltransferase inhibitor, a low-density lipoprotein receptor promoter, a microsomal triglyceride transfer protein inhibitor and an anorectic.